Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series

Ipilimumab is a fully human, monoclonal antibody directed against Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) that has demonstrated a survival benefit and durable disease control in patients with advanced melanoma. Ipilimumab is associated with potentially serious immune-related adverse events, includ...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravi, Sowmya, Spencer, Kristen, Ruisi, Mary, Ibrahim, Nageatte, Luke, Jason J, Thompson, John A, Shirai, Keisuke, Lawson, David, Bartell, Heddy, Kudchadkar, Ragini, Gunter, Ngoc Thi, Mehnert, Janice M, Lipson, Evan J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195895/
https://www.ncbi.nlm.nih.gov/pubmed/25317333
http://dx.doi.org/10.1186/s40425-014-0033-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195895/
https://www.ncbi.nlm.nih.gov/pubmed/25317333
http://dx.doi.org/10.1186/s40425-014-0033-1

Ejemplares similares